A multi stage model is described for estimating the age and two stage specific prevalence of cancer. The disease evolution is considered as an inhomogeneous Poisson process in the Lexis diagram. Prevalences are estimated from the basic epidemiological measures (stage specific incidences and survivals). A piecewise constant hazard model is used to estimate the transition rates constructing a finite partition of age and, where it is the case, of duration. Moreover, variance calculations are described. An application to breast cancer in the Hérault (France) population is presented.
Get full access to this article
View all access options for this article.
References
1.
Byrne J , Kessler LG , Devesa SS.The prevalence of cancer among adults in the United States . Cancer1992; 68: 2154-2159 .
2.
Feldman AR , Kessler L , Myers MH , Naughton MD.The prevalence of cancer.Estimates basedon the Connecticut Tumor Registry . New England Journal of Medicine1986; 315: 1394-1397 .
3.
Gail MH , Kessler L , Midthune D , Scoppa S.Two approaches for estimating disease prevalence from population-based registries of incidence and total mortality . Biometrics1999; 55: 1137-1144 .
4.
Capocaccia R , De Angelis R.Estimating the completeness of prevalence based on cancer registry data . Statistics in Medicine1997; 16: 425-440 .
5.
Merrill RM , Capocaccia R , Feuer EJ , Mariotto A.Cancer prevalence estimates based on tumor registry data in the SEER program . International Journal of Epidemiology2000; 29: 197-207 .
6.
Verdecchia A , Capocaccia R.A method for the estimation of chronic disease morbidity and trends from mortality data . Statistics in Medicine1989; 8: 201-216 .
7.
Capocaccia R.Relationships between incidence and mortality in non-reversible diseases . Statistics in Medicine1993; 12: 2395-2415 .
8.
Keiding N.Age-specific incidence and prevalence: a statistical perspective . Journal of the Royal Statistical Society, Series A1991; 154: 371-412 .
9.
Capocaccia R , Colonna M , Corazziari I , De Angelis R , Francisci S , Mocheli A , Mugno E and the EUROPREVAL Working Group . Measuring cancer prevalence in Europe: the EUROPREVAL project . Annals of Oncology2002; 13: 831-839 .
10.
Micheli A , Mugno E , Krogh V , Quinn MJ , Coleman M , Hakulinen T , Gatta G , Berrino F , Capocaccia R and the EUROPREVAL Working Group . Cancer prevalence in European registry areas . Annals of Oncology2002; 13: 840-865 .
11.
Brillinger DR.The natural variability of vital rates and associated statistics (with discussion) . Biometrics1986; 42: 693-734 .
12.
Keiding N.Statistical inference in the Lexis diagram . Philosophical Transactions of the Royal Society London A1990; 332: 487-509 .
13.
DeGroot MH , Ferber R , Frankel MR , Seneta E , Watson GS.Encyclopedia of statistical sciences . Chichester: John Wiley & Sons:1988, 8: 646-647 .
Colonna M , Hedelin G , Estève J , Grosclaude P , Launoy G , Buémi A , Arveux P , Tretarre B , Chaplain G , Macé Lesec’h J , Raverdy N , Carli PM , Menegoz F , Faivre J.National cancer prevalence estimate in France . International Journal of Cancer2000; 87: 301-304 .
16.
Ménégoz F, Chérié-Challine L, Grosclaude P, Jougla E. Réseau français des registres des cancers FRANCIM. Le Cancer en France: incidence et mortalité: situation en 1995, évolution entre 1975 et 1995. Paris: Broché, 1998.
17.
Micheli A , Francisci S , Krogh V , Rossi AG , Crosignani P for the ITAPREVAL Working Group . Cancer prevalence in Italian cancer registry areas: the ITAPREVAL study . Tumori1999; 85: 309-369 .
